February 17, 2026- Medtronic plc announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.
Q3 Key Highlights
- Revenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidance
- GAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-point
- Company reiterates FY26 organic revenue growth and EPS guidance
- Cardiac Ablation Solutions revenue increased 80%, including 137% in the U.S., on strength of pulsed field ablation (PFA) portfolio
- Secured CE Mark for Sphere-360™ and initiated U.S. pivotal trial
- Secured U.S. FDA clearance for Hugo™ robotic-assisted surgery; first cases completed this month
- Secured U.S. FDA clearance for Stealth AXiS™ Surgical System for spinal procedures
- Diabetes revenue increased 8.3% led by double-digit strength in International markets
- Executing M&A strategy with two key transactions in the quarter: CathWorks in Coronary and Renal Denervation and Anteris in Structural Heart